Yue Xiang Yue Health Submits IPO Prospectus in March 2026
IASO Biotechnology
Cancer Treatment New Drug Developer
E-Health Now
Lifecycle Intelligent Health Management Service Provider
Healthgen Biotech
Research and Product Developer of Plant-derived Recombinant Protein Expression Technology
Century Healthcare
Medical Device Manufacturer, R&D, and Distributor
TG ImmunoPharma
ImmunoPharma Developer
Click to follow? | Focus on Global Biomedical Investment
In March, the industry's grand event BIOCHINA 2026 opened in Suzhou. Mr. Zhu Pai, CEO of Efung Capital, was invited to attend. On the 13th, he participated in the roundtable forum "LP-GP Ecosystem: 'Synergy' in Policy, Capital, and Innovation," engaging in an in-depth dialogue with industry peers. Meanwhile, the companies invested in by Efung Capital also shone brightly at this conference: IASO Bio and other enterprises made significant appearances, showcasing the cutting-edge strength of China's innovative pharmaceutical companies to the industry.
Outside the conference, numerous portfolio companies of Efung Capital have also made significant breakthroughs in their respective fields, demonstrating vigorous development momentum.
01
Progress of Portfolio Companies' IPOs and Financing
E-Health Now
· AI Agent Reconstructs the Ecosystem of Healthcare Management Services
E-Health Now
· AI Agent Reconstructs the Ecosystem of Healthcare Management Services
Recently, E-Health Now, a leading artificial intelligence digital health service technology group in China, officially announced the completion of several hundred million RMB in financing.DThis round of financing was jointly led by EF Capital, Yahelon, Ventech China, and Fengqiao Capital.
02
Clinical and Commercial Dynamics of Invested Companies
Healthgen Biotech
· Aofumin® Phase IV Clinical Trial Completes First Dosing
Recently, Healthgen Biotech's recombinant human albumin (rice) Afulmin® "In Hypoalbuminemia and/or insufficient blood volume requiring emergency treatment in patients for safety and efficacy"IV The first patient was enrolled and the first dosing was completed in the Phase I clinical study.IV Entering the substantive clinical research stage.
Century Healthcare
· Completed by multiple hospitalsInnermedical Intravitreal Surgery
Healthgen Biotech
· Aofumin® Phase IV Clinical Trial Completes First Dosing
Recently, Healthgen Biotech's recombinant human albumin (rice) Afulmin® "In Hypoalbuminemia and/or insufficient blood volume requiring emergency treatment in patients for safety and efficacy"IV The first patient was enrolled and the first dosing was completed in the Phase I clinical study.IV Entering the substantive clinical research stage.
Healthgen Biotech
· Aofumin® Phase IV Clinical Trial Completes First Dosing
Healthgen Biotech
· Aofumin® Phase IV Clinical Trial Completes First Dosing
Healthgen Biotech
· Aofumin® Phase IV Clinical Trial Completes First Dosing
Recently, Healthgen Biotech's recombinant human albumin (rice) Afulmin® "In Hypoalbuminemia and/or insufficient blood volume requiring emergency treatment in patients for safety and efficacy"IV The first patient was enrolled and the first dosing was completed in the Phase I clinical study.IV Entering the substantive clinical research stage.
Century Healthcare
· Completed by multiple hospitalsInnermedical Intravitreal Surgery
Century Healthcare
· Completed by multiple hospitalsInnermedical Intravitreal Surgery
Recently, Taiyuan Aier Eye Hospital in Shanxi Province completed the first case of cataract surgery using the Versa product in China, and it was also the first case in Shanxi Province.®Ultra-EDoFExtended Depth-of-Focus Intraocular Lens Implantation Surgery; Beijing Huaxia Minzhong Eye Hospital Completes the First Batch of Wan Shi An Nationwide®Ultra-EDoF Implantation Surgery of Artificial Crystalline Lens; Zhengzhou Apex Eye Hospital Implants the First Diffractive TypeEDoFIntraocular Lens (VisionEase)®Ultra-EDoF), etc.
Innermedical
· "Gemini" Lands at Macao Union Hospital, Assisting in Setting a New Benchmark for Precision Medicine in the Greater Bay Area
Innermedical
· "Gemini" Lands at Macao Union Hospital, Assisting in Setting a New Benchmark for Precision Medicine in the Greater Bay Area
Innermedical
· "Gemini" Lands at Macao Union Hospital, Assisting in Setting a New Benchmark for Precision Medicine in the Greater Bay Area
Innermedical
· "Gemini" Lands at Macao Union Hospital, Assisting in Setting a New Benchmark for Precision Medicine in the Greater Bay Area
Innermedical"Gemini" Mini-Probe Endoscopic Ultrasound Officially Launched at Macao Medical Center of Peking Union Medical College Hospital, Injecting Innovative Momentum into the High-Quality Development of Healthcare in Macao and the Guangdong-Hong Kong-Macao Greater Bay Area.
· Led by Three Ministries, National Electronic Gastrointestinal Endoscopy Promotion and Application Project Officially Launched
On March 28, the "2025 High-End Medical Equipment Promotion and Application Project – Endoscopic Ultrasound Promotion and Application Project," jointly promoted by three ministries—the Ministry of Industry and Information Technology, the National Health Commission, and the National Medical Products Administration—was officially launched. Led by West China Hospital of Sichuan University as the lead hospital and Innermedical as the lead enterprise, the project brings together 13 participating hospitals and 12 cooperative hospitals to work collaboratively.
· Led by Three Ministries, National Electronic Gastrointestinal Endoscopy Promotion and Application Project Officially Launched
On March 28, the "2025 High-End Medical Equipment Promotion and Application Project – Endoscopic Ultrasound Promotion and Application Project," jointly promoted by three ministries—the Ministry of Industry and Information Technology, the National Health Commission, and the National Medical Products Administration—was officially launched. Led by West China Hospital of Sichuan University as the lead hospital and Innermedical as the lead enterprise, the project brings together 13 participating hospitals and 12 cooperative hospitals to work collaboratively.
· Led by Three Ministries, National Electronic Gastrointestinal Endoscopy Promotion and Application Project Officially Launched
· Led by Three Ministries, National Electronic Gastrointestinal Endoscopy Promotion and Application Project Officially Launched
· Led by Three Ministries, National Electronic Gastrointestinal Endoscopy Promotion and Application Project Officially Launched
On March 28, the "2025 High-End Medical Equipment Promotion and Application Project – Endoscopic Ultrasound Promotion and Application Project," jointly promoted by three ministries—the Ministry of Industry and Information Technology, the National Health Commission, and the National Medical Products Administration—was officially launched. Led by West China Hospital of Sichuan University as the lead hospital and Innermedical as the lead enterprise, the project brings together 13 participating hospitals and 12 cooperative hospitals to work collaboratively.
TGI
· Professor Tian Zhigang, the founder, is invited to attend the BIOCHINA2026 conference.
TGI
· Professor Tian Zhigang, the founder, is invited to attend the BIOCHINA2026 conference.
3Month12Day~14Day,BIOCHINA 2026The 11th EBC Biotechnology Exhibition was held in Suzhou.Leading Scholar in the International Immunology Field, Founder of TGIProfessor Tian Zhigang Invited to Three Core Forums.
Kashi Biotech
· Debut at 2026 CACLP
Kashi Biotech
· Debut at 2026 CACLP
Kashi Biotech
· Debut at 2026 CACLP
Kashi Biotech
· Debut at 2026 CACLP
3Month21Date23On [date], the 25th China International Exhibition for Laboratory Medicine, Blood Transfusion Instruments, and Reagents was held in Xiamen. Kaishi Biotech, as a leading company in China,CDMOService providers, showcasing multiple core achievements.
HaploX
· Exclusive Strategic Cooperation Reached with IASO Bio
HaploX
· Exclusive Strategic Cooperation Reached with IASO Bio
HaploX
· Exclusive Strategic Cooperation Reached with IASO Bio
HaploX
· Exclusive Strategic Cooperation Reached with IASO Bio
Recently,HaploX and IASO Bio Exclusive Strategic Cooperation Signing Ceremony Successfully Held. This cooperation重磅推出“Closed Zero-Pollution Medium-to-High Throughput Sequencing Full-Process Solution”。
Typhogen Bio
· New Drug for Preventing Infant RSV Infection - RSV Monoclonal Antibody Accelerates Market Launch Process
Typhogen Bio
· New Drug for Preventing Infant RSV Infection - RSV Monoclonal Antibody Accelerates Market Launch Process
Typhogen Bio
· New Drug for Preventing Infant RSV Infection - RSV Monoclonal Antibody Accelerates Market Launch Process
Typhogen Bio
· New Drug for Preventing Infant RSV Infection - RSV Monoclonal Antibody Accelerates Market Launch Process
3Month2Recently, the recombinant long-acting anti-respiratory syncytial virus fully human monoclonal antibody – Ruitoweibai Monoclonal Antibody Injection, developed by Zhuhai Tanomab, has been officially included in the priority review and approval process of the Center for Drug Evaluation under the National Medical Products Administration.
03
Approval Status of New Drugs and Devices from Invested Companies
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
On March 25, the National Medical Products Administration officially released information, byChongqing Yu Yan Pharmaceutical(Developed by Eminence Biotech Holdings)Injectable Recombinant Botulinum Toxin Type A(Approval No. S20260019) has been approved for marketing, isChina's First, World's FirstBotulinum Toxin Type A produced using recombinant technology.
RingCode Biotech
· HM2003 Injection Receives FDA Clinical Approval and Pediatric Rare Disease Designation
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
On March 25, the National Medical Products Administration officially released information, byChongqing Yu Yan Pharmaceutical(Developed by Eminence Biotech Holdings)Injectable Recombinant Botulinum Toxin Type A(Approval No. S20260019) has been approved for marketing, isChina's First, World's FirstBotulinum Toxin Type A produced using recombinant technology.
RingCode Biotech
· HM2003 Injection Receives FDA Clinical Approval and Pediatric Rare Disease Designation
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
On March 25, the National Medical Products Administration officially released information, byChongqing Yu Yan Pharmaceutical(Developed by Eminence Biotech Holdings)Injectable Recombinant Botulinum Toxin Type A(Approval No. S20260019) has been approved for marketing, isChina's First, World's FirstBotulinum Toxin Type A produced using recombinant technology.
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
On March 25, the National Medical Products Administration officially released information, byChongqing Yu Yan Pharmaceutical(Developed by Eminence Biotech Holdings)Injectable Recombinant Botulinum Toxin Type A(Approval No. S20260019) has been approved for marketing, isChina's First, World's FirstBotulinum Toxin Type A produced using recombinant technology.
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
Yinming Biotech
· China's First, World's First Recombinant Type A Botulinum Toxin Approved for Marketing
On March 25, the National Medical Products Administration officially released information, byChongqing Yu Yan Pharmaceutical(Developed by Eminence Biotech Holdings)Injectable Recombinant Botulinum Toxin Type A(Approval No. S20260019) has been approved for marketing, isChina's First, World's FirstBotulinum Toxin Type A produced using recombinant technology.
RingCode Biotech
· HM2003 Injection Receives FDA Clinical Approval and Pediatric Rare Disease Designation
RingCode Biotech
· HM2003 Injection Receives FDA Clinical Approval and Pediatric Rare Disease Designation
3 Month11 Day,EpiVax BioAnnouncing the second core circular product independently developedRNAInnovative Drugs HM2003 Injectable solution officially received approval from the U.S. Food and Drug Administration (FDA) Clinical Trial Permit.
Hannuo Healthcare
· China-Made "Artificial Lung" Receives U.S. FDA Approval
Hannuo Healthcare
· China-Made "Artificial Lung" Receives U.S. FDA Approval
Hannuo Healthcare
· China-Made "Artificial Lung" Receives U.S. FDA Approval
Hannuo Healthcare
· China-Made "Artificial Lung" Receives U.S. FDA Approval
3Month16Day,Hannuo Medical's Self-Developed Core Product of Extracorporeal Membrane Oxygenation System"Disposable Membrane Oxygenator" Officially Receives Approval from the U.S. Food and Drug Administration (FDA) of510(k)Access Permit.
IASO Bio
· IASO Bio's CAR-T Drug Idecabtagene Vicleucel Injection Granted Implied Approval by Japan PMDA for Phase 2/3 Clinical Trials in Multiple Myeloma
IASO Bio
· IASO Bio's CAR-T Drug Idecabtagene Vicleucel Injection Granted Implied Approval by Japan PMDA for Phase 2/3 Clinical Trials in Multiple Myeloma
IASO Bio
· IASO Bio's CAR-T Drug Idecabtagene Vicleucel Injection Granted Implied Approval by Japan PMDA for Phase 2/3 Clinical Trials in Multiple Myeloma
IASO Bio
· IASO Bio's CAR-T Drug Idecabtagene Vicleucel Injection Granted Implied Approval by Japan PMDA for Phase 2/3 Clinical Trials in Multiple Myeloma
3Month24The other day, IASO Bio announcedIts independently developed fully human targetedBCMA CAR-TCell Therapy Product Idecabtagene Vicleucel Injection (Fucaso) The clinical trial application has received tacit approval from Japan's Pharmaceuticals and Medical Devices Agency.
LingShi Quality Source
· World’s First TCR×CD3 Bispecific Antibody Targeting RAS G12V Mutation Approved for U.S. Clinical Trials
LingShi Quality Source
· World’s First TCR×CD3 Bispecific Antibody Targeting RAS G12V Mutation Approved for U.S. Clinical Trials
LingShi Quality Source
· World’s First TCR×CD3 Bispecific Antibody Targeting RAS G12V Mutation Approved for U.S. Clinical Trials
LingShi Quality Source
· World’s First TCR×CD3 Bispecific Antibody Targeting RAS G12V Mutation Approved for U.S. Clinical Trials
3Month12Day, Lingzhi Quality Source BiotechES502Injection Solution ObtainedFDAApprovalIPhase clinical trial, used for treatingRAS G12VPatients with advanced solid tumors harboring mutations.
Microchip Biotech
· World's First! Chipscreen Biosciences' Combination Therapy for Type 2 Diabetes, Ciglitazone Metformin Sustained-Release Tablets, Approved for Clinical Trials
3Month16On [date], Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been Approved by the National Medical Products Administration (NMPA).NMPA) Approval.
· Original Brain-Penetrant PRMT5-MTA Inhibitor CS08399 Approved for Clinical Trials
3Month13The other day, Chengdu Chipscreen Pharmaceuticals, a wholly-owned subsidiary of Chipscreen Biosciences, announced that1Original New DrugCS08399Tablets for the treatment of methylthioadenosine phosphorylase(MTAP)Clinical Trial Applications for Missing Solid Tumors and Lymphomas (IND) has been approved by the National Medical Products Administration.
Microchip Biotech
· World's First! Chipscreen Biosciences' Combination Therapy for Type 2 Diabetes, Ciglitazone Metformin Sustained-Release Tablets, Approved for Clinical Trials
3Month16On [date], Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been Approved by the National Medical Products Administration (NMPA).NMPA) Approval.
· Original Brain-Penetrant PRMT5-MTA Inhibitor CS08399 Approved for Clinical Trials
3Month13The other day, Chengdu Chipscreen Pharmaceuticals, a wholly-owned subsidiary of Chipscreen Biosciences, announced that1Original New DrugCS08399Tablets for the treatment of methylthioadenosine phosphorylase(MTAP)Clinical Trial Applications for Missing Solid Tumors and Lymphomas (IND) has been approved by the National Medical Products Administration.
Microchip Biotech
· World's First! Chipscreen Biosciences' Combination Therapy for Type 2 Diabetes, Ciglitazone Metformin Sustained-Release Tablets, Approved for Clinical Trials
3Month16On [date], Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been Approved by the National Medical Products Administration (NMPA).NMPA) Approval.
· Original Brain-Penetrant PRMT5-MTA Inhibitor CS08399 Approved for Clinical Trials
Microchip Biotech
· World's First! Chipscreen Biosciences' Combination Therapy for Type 2 Diabetes, Ciglitazone Metformin Sustained-Release Tablets, Approved for Clinical Trials
3Month16On [date], Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been Approved by the National Medical Products Administration (NMPA).NMPA) Approval.
3Month16On [date], Chipscreen Biosciences and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceuticals announced that the company's self-developed treatment2Clinical Trial Application for Sodium Siglitazar and Metformin Hydrochloride Sustained-Release Tablets for Type Diabetes has been Approved by the National Medical Products Administration (NMPA).NMPA) Approval.
· Original Brain-Penetrant PRMT5-MTA Inhibitor CS08399 Approved for Clinical Trials
3Month13The other day, Chengdu Chipscreen Pharmaceuticals, a wholly-owned subsidiary of Chipscreen Biosciences, announced that1Original New DrugCS08399Tablets for the treatment of methylthioadenosine phosphorylase(MTAP)Clinical Trial Applications for Missing Solid Tumors and Lymphomas (IND) has been approved by the National Medical Products Administration.
04
Honors of Invested Enterprises
Selected for the 11th Batch of the "Directory of Excellent Domestic Medical Device Products"
· BIOPSEE® Beixi® Confocal Microendoscope, BIOPSEE® Beixi® Ultra-thin Probe
Selected for the 11th Batch of the "Directory of Excellent Domestic Medical Device Products"
· BIOPSEE® Beixi® Confocal Microendoscope, BIOPSEE® Beixi® Ultra-thin Probe
Selected as one of the key specialized and innovative small and medium-sized enterprises in Zhejiang Province by the Zhejiang Provincial Department of Economy and Information Technology for 2026 ("Key Provincial Specialized Enterprises").
· Hangzhou Huamai, Nyloon Biotech
Selected as one of the key specialized and innovative small and medium-sized enterprises in Zhejiang Province by the Zhejiang Provincial Department of Economy and Information Technology for 2026 ("Key Provincial Specialized Enterprises").
· Hangzhou Huamai, Nyloon Biotech
Awarded by the National Center for ADR Monitoring as an Outstanding Enterprise in the 2025 Monitoring and Evaluation of Adverse Reactions to Pharmaceuticals, Medical Devices, and Cosmetics
· Real Biotech
Awarded by the National Center for ADR Monitoring as an Outstanding Enterprise in the 2025 Monitoring and Evaluation of Adverse Reactions to Pharmaceuticals, Medical Devices, and Cosmetics
· Real Biotech
Debut at AACR 2026: Poster Presentation of Two Research Achievements
· TGI
Debut at AACR 2026: Poster Presentation of Two Research Achievements
· TGI
AwardedThird Prize in the First Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition
· Huayuan Regenerative Medicine
"Selected as one of the 'Top Ten Researches in Breast Cancer Field in 2025'"
· Huahao Zhongtian's Utidelone in the Treatment of Brain Metastases in Breast Cancer
RongAwarded the 2026 Forbes China Industry Development Leading Enterprise
· Aomo Pharmaceuticals, Real Biotech
RongPublished in the international professional journal of critical care medicine, "ICU Management & Practice"
· Hannuo Medical Lifemotion® ECMO System
05
Yifeng Honor
AwardedThird Prize in the First Guangdong-Hong Kong-Macao Greater Bay Area Entrepreneurship Competition
· Huayuan Regenerative Medicine
"Selected as one of the 'Top Ten Researches in Breast Cancer Field in 2025'"
· Huahao Zhongtian's Utidelone in the Treatment of Brain Metastases in Breast Cancer
"Selected as one of the 'Top Ten Researches in Breast Cancer Field in 2025'"
· Huahao Zhongtian's Utidelone in the Treatment of Brain Metastases in Breast Cancer
RongAwarded the 2026 Forbes China Industry Development Leading Enterprise
· Aomo Pharmaceuticals, Real Biotech
RongAwarded the 2026 Forbes China Industry Development Leading Enterprise
· Aomo Pharmaceuticals, Real Biotech
RongPublished in the international professional journal of critical care medicine, "ICU Management & Practice"
· Hannuo Medical Lifemotion® ECMO System
RongPublished in the international professional journal of critical care medicine, "ICU Management & Practice"
· Hannuo Medical Lifemotion® ECMO System
RongPublished in the international professional journal of critical care medicine, "ICU Management & Practice"
· Hannuo Medical Lifemotion® ECMO System
05
Yifeng Honor
06
Yifeng Highlights
Yifeng Capital CEO Zhu Pai AttendedBIOCHINA 2026
· March，The 11th EMBIO Biotechnology Industry Conference (BIOCHINA 2026)Grandly convened in Suzhou.CEO of Efund Capital, Zhu PaiInvited to attend the core session of the conference, the "Global Investment Forum," and engaged in an in-depth dialogue with industry peers on the theme of "LP-GP Ecosystem Encirclement: 'Synergy' in Policy, Capital, and Innovation."
06
Yifeng Highlights
Yifeng Capital CEO Zhu Pai AttendedBIOCHINA 2026
· March，The 11th EMBIO Biotechnology Industry Conference (BIOCHINA 2026)Grandly convened in Suzhou.CEO of Efund Capital, Zhu PaiInvited to attend the core session of the conference, the "Global Investment Forum," and engaged in an in-depth dialogue with industry peers on the theme of "LP-GP Ecosystem Encirclement: 'Synergy' in Policy, Capital, and Innovation."
06
Yifeng Highlights
Yifeng Capital CEO Zhu Pai AttendedBIOCHINA 2026
· March，The 11th EMBIO Biotechnology Industry Conference (BIOCHINA 2026)Grandly convened in Suzhou.CEO of Efund Capital, Zhu PaiInvited to attend the core session of the conference, the "Global Investment Forum," and engaged in an in-depth dialogue with industry peers on the theme of "LP-GP Ecosystem Encirclement: 'Synergy' in Policy, Capital, and Innovation."
✦
Recommended Reading
✦
NorthX Life SciTech STAR IPO
✦
Recommended Reading
✦
NorthX Life SciTech STAR IPO
NorthX Life SciTech STAR IPO
Healthgen Biotech STAR Market IPO
Bokang Vision Cloud Hong Kong Main Board IPO
Sino-Harvest Bio Hong Kong Main Board IPO
Quanxin Biotech Hong Kong Main Board IPO
Against the Current, Moving Forward with Time
3D Medicines Hong Kong Main Board IPO
Healthgen Biotech's STAR Market IPO
A Decade of Honing the Sword – Its Blade Will Surely Gleam When Drawn
Athena Med's STAR Market IPO
Looking forward to your
Share
Like
In
Healthgen Biotech STAR Market IPO
Healthgen Biotech STAR Market IPO
Healthgen Biotech STAR Market IPO
Bokang Vision Cloud Hong Kong Main Board IPO
Bokang Vision Cloud Hong Kong Main Board IPO
Sino-Harvest Bio Hong Kong Main Board IPO
Quanxin Biotech Hong Kong Main Board IPO
Against the Current, Moving Forward with Time
3D Medicines Hong Kong Main Board IPO
Healthgen Biotech's STAR Market IPO
A Decade of Honing the Sword – Its Blade Will Surely Gleam When Drawn
Athena Med's STAR Market IPO
Looking forward to your
Share
Like
In